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Purpose: The UK Glaucoma Treatment Study (UKGTS) demonstrated the effectiveness of 47 
an intraocular pressure-lowering drug in patients with glaucoma using visual field 48 
progression as a primary outcome. We now test the hypothesis that responses on patient 49 
reported outcome measures (PROMs – secondary outcome measure) differ between 50 
patients receiving a topical prostaglandin analogue (Latanoprost) or placebo eye drops 51 
in UKGTS. 52 
Design: Multi-centre, randomised, triple-masked, placebo-controlled trial. 53 
Participants: Newly diagnosed glaucoma patients recruited into the UKGTS with baseline 54 
and exit PROM data (n= 182 and n=168 patients from the treatment and placebo group, 55 
respectively).  56 
Methods: The UKGTS was a multi-centre, randomised, triple-masked, placebo-controlled 57 
trial, where patients with newly diagnosed open angle glaucoma were allocated to 58 
receive Latanoprost (treatment) or placebo (trial registration number: 59 
ISRCTN96423140); the observation period was 24-months. Patients completed general 60 
health PROMs (EQ-5D and SF-36) and PROMs specific to glaucoma (GQL-15 and GAL-9) 61 
at baseline and at exit from the trial. Percentage change between baseline and exit 62 
measurement on PROMs were calculated for each patient and compared between 63 
treatment arms. In addition, differences between stable patients (n=272) and those with 64 
glaucomatous progression (n=78), as determined by visual field change (primary 65 
outcome), were assessed.  66 
Main Outcome Measure: PROMs on health-related and vision-related quality of life. 67 
Results: Average percentage change on PROMs was similar for patients in both arms of 68 
the trial with no statistically significant differences between treatment and placebo 69 
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groups (EQ-5D, p = 0.98; EQ-5D VAS, p = 0.88; SF-36, p = 0.94, GQL-15, p = 0.66; GAL-9, p 70 
= 0.87). There were statistically significant differences between stable and progressing 71 
patients, as determined by visual fields, on glaucoma-specific PROMs (GQL-15, p = 0.02; 72 
GAL-9, p = 0.02) but not on general health PROMs (EQ-5D, p = 0.62; EQ-5D VAS, p = 0.23; 73 
SF-36, p = 0.65)  74 
Conclusions: Average change in PROMs on health-related and vision-related quality of life 75 
was similar for the treatment and placebo group in the UKGTS. PROMs, specifically those 76 
used in the UKGTS, may not be sensitive enough to be used as a primary endpoint in 77 
clinical trials when participants have newly diagnosed early stage glaucoma. 78 
  79 
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Intraocular pressure (IOP) is currently the only modifiable risk factor for disease 80 
progression in glaucoma. All therapies approved for the treatment of glaucoma are 81 
licenced on their ability to reduce patients’ IOP. Yet, the foremost outcome when treating 82 
glaucoma is to maintain what is most important to the patient, vision-related quality of 83 
life. (1) Randomised clinical trials have provided evidence for the visual field preserving 84 
benefit of reducing IOP. (2-12) Recently, the United Kingdom Glaucoma Treatment Study 85 
(UKGTS) evidenced the effectiveness of an IOP lowering treatment in patients with 86 
glaucoma using visual field deterioration determined by standard automated perimetry 87 
as the primary outcome measure over a two-year follow-up period. (12) 88 
Typically, outcome measures in clinical trials are selected on their sensitivity to 89 
clinically meaningful changes in disease severity. However, diagnostic test 90 
measurements taken in the clinic do not directly capture the impact of glaucoma on the 91 
patient’s life. (13) IOP is not a direct measure of glaucomatous optic neuropathy. Visual 92 
fields, however, indicate functional ability, and are therefore more closely associated with 93 
vision-related quality of life than IOP. Patient reported outcome measures (PROMs) are 94 
instruments derived from standardised, validated questionnaires that are used to 95 
measure perceived health status, functional status, or health-related quality of life. Asking 96 
a patient directly is an effective way to ascertain how someone feels about their condition 97 
and how it might be affecting their well-being. (14) PROMs can also be readily translated 98 
into measures of cost-effectiveness. 99 
Use of PROMs in clinical research has increased in recent years, (15) and this is 100 
beginning to be mirrored in glaucoma research, (16) where a catalogue of vision-specific 101 
PROMs are now available. (17) PROMs are also becoming more frequently used in clinical 102 
trials, (18) including in ophthalmology trials, (19- 23). Typically, PROMs are used to 103 
complement a more clinical primary outcome in trials. However, The United States Food 104 
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and Drug Administration endorses the use of PROMs as primary endpoints in glaucoma 105 
trials, (24) and this has been implemented in recent glaucoma trials. (25-27) An important 106 
attribute of a clinical trial outcome measure is to be sensitive enough to detect differences 107 
between a treatment and a control group. This is particularly true for glaucoma treatment 108 
trials because the disease process is slow and changes to vision can be challenging to 109 
measure. Moreover, disease progression in glaucoma is often unnoticeable to the patient 110 
in the early stages of disease. (28) A lack of sensitivity may necessitate prolonged trial 111 
duration which can add to the delay of drug development. For this reason, the sensitivity 112 
of PROMs when used as outcome measures in glaucoma trials should be scrutinised and 113 
this is the subject of our study. Specifically, we analyse PROM responses from patients in 114 
the UKGTS to test the hypothesis that these measures can determine differences between 115 
the groups randomised to treatment or placebo.  116 
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Methods 117 
In this study, we analyse the responses on PROMs of patients enrolled into the UKGTS, a 118 
multi-centre, randomised, triple-masked, placebo-controlled trial assessing visual 119 
function preservation in newly diagnosed open-angle glaucoma patients (trial 120 
registration number: ISRCTN96423140). Patients recruited from ten eye clinics 121 
throughout the United Kingdom were randomly allocated to receive an IOP reducing 122 
prostaglandin analogue Latanoprost (0.005%) or placebo eye drops. The UKGTS, and the 123 
subsequent analysis of anonymised data in this study, adhered to the tenets of the 124 
Declaration of Helsinki and was approved by local institutional review boards (ethics 125 
approval reference: 09/H0721/56). Study participants provided written informed 126 
consent. 127 
A total of 461 patients from 516 enrolled were analysed in the trial (Latanoprost 128 
N = 231, placebo N = 230). Patients in the UKGTS were scheduled to perform a series of 129 
11 visual field examinations during a 2-year observation period. Visual field progression 130 
was used as the primary endpoint in the trial. Progression analysis was performed in the 131 
Humphrey Field Analyser Guided Progression Analysis (GPA) software; a sensitive 132 
technique that considers changes at individual points (test locations) in the visual field. 133 
Progression was defined as at least three visual field locations worse than baseline at the 134 
5% levels in two consecutive reliable visual fields and at least three visual field locations 135 
worse than baseline at the 5% levels in the two subsequent consecutive reliable visual 136 
fields; the locations identified in the first and second pair were not required to be 137 
identical. Details of the trial design and the trial outcome are published elsewhere. (12; 29) 138 
In short, the risk of visual field progression was significantly lower in the treatment group 139 
than in the placebo group (adjusted hazard ratio 0.44 [95% confidence interval (CI) 0.28-140 
0.69]). 141 
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PROMs were included as secondary outcome measures in UKGTS. PROMs were 142 
self-reported at patients’ baseline and final visit and were administered by a trial 143 
researcher. In the event of a patient meeting the primary trial endpoint, PROMs were 144 
completed upon the patients’ withdrawal from the trial. The PROMs used in UKGTS were 145 
as follows: 146 
European Quality of Life in 5 dimensions (EQ-5D) is a classification of general 147 
health status. (30) EQ-5D assesses five attributes: mobility, self-care, usual activity, 148 
pain/discomfort, and anxiety/depression. We used the three-level measure meaning 149 
each dimension has three possible outcomes: no problems, some problems, and severe 150 
problems. Patients with no problems across all five attributes will produce a five-digit 151 
health status code of 11111. Patients with severe problems will score 33333. Five-digit 152 
codes were translated into a single health state score using an existing scoring system 153 
which is generated from a UK population sample. (30) Included in the EQ-5D is a visual 154 
analogue scale (EQ-5D VAS) where patients are asked to score their own health between 155 
0 and 100 (where 0 and 100 are worst and the best imaginable health). EQ-5D is the most 156 
commonly used general health PROM and is recommended in The National Institute for 157 
Health and Care Excellence guidelines for health economic analysis in the United 158 
Kingdom. (31) Furthermore, following recommendations by the United States Public 159 
Health Service, (32) there now exists a large database of EQ-5D derived health statistics 160 
for the American population, too. (33) 161 
Short Form-36 (SF-36) is another general health instrument featuring 36 items 162 
across eight domains relating to: physical functioning, role limitation due to physical 163 
problems, emotional problems, bodily pain, general health, social functioning, vitality, 164 
and mental health. (34) Responses are made on Likert-type scales and the 36 individual 165 
items can be translated to give a global score for general health (ranging 0-100) where 166 
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lower scores reflect poorer self-reported health. Following the International Quality of 167 
Life Assessment Project translation of SF-36 into several languages, (35) this PROM has 168 
become frequently used in cost-utility studies. (36) 169 
Glaucoma Quality of Life (GQL-15) instrument has 15-items and is disease 170 
specific being designed to assess the impact of glaucoma on vision-related quality of life. 171 
(37) The GQL-15 was derived from an initial 62-item pilot questionnaire; the 15-items 172 
were included in the final instrument due to their strong relationship with visual field 173 
loss in glaucoma patients. (38) GQL-15 has four subscales: central and near vision, 174 
peripheral vision, mobility, and glare/dark adaptation. Scoring is based on five-point 175 
Likert-type scales where a response of 5 denotes severe difficulty and 1 indicates no 176 
difficulty. The measurement scale ranges from 15 to 75 where higher scores represent 177 
poorer vision-related quality of life. The instrument has been used in well-designed 178 
cross-sectional studies assessing the impact of glaucoma on patients’ quality of life. (39, 40) 179 
GQL-15 has previously been subjected to Rasch analysis to produce the 9-item 180 
Glaucoma Activity Limitation (GAL-9) PROM. (41) This instrument consists of a subset 181 
of nine items from the original GQL-15 and is considered to better reflect the effects of 182 
glaucoma on visual function. (41) GAL-9 has good external validity as scores from the 183 
instrument have been shown to correlate well with visual acuity and visual field scores. 184 
Furthermore, the GAL-9 is quicker to complete than the GQL-15 because it has fewer 185 
items. (41) In addition to our analysis of GQL-15 responses, we repeat the analysis on the 186 
items included in the GAL-9 for patients in the UKGTS. 187 
For the data analysis, responses on the PROMs at baseline and exit were 188 
transposed into percentage scores. (The exit visit was at 24-months or, for progressing 189 
patients, at the visit when progression was confirmed). Differences between these scores 190 
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were used to detect the degree of change in each PROM between first and last trial visit. 191 
For example, no change is indicated by zero and scores greater than 0% indicate 192 
worsening on PROMs, i.e. patients report more problems on exit from the trial than at 193 
baseline; negative values indicate improvement from baseline. Two-sample independent 194 
t-tests were used to determine whether there was a statistically significant difference in 195 
change on PROMs between the two trial groups (treatment and placebo). 196 
Additionally, we assessed whether statistically significant differences in PROM 197 
responses could be observed between patients who remained stable during the UKGTS 198 
and those who experienced the primary trial endpoint. We included this additional 199 
analysis as it was anticipated that the largest difference in score for health-related and 200 
vision-related quality of life would be observed between these two patient groups. 201 
Results 202 
 Complete baseline and exit PROM data were available for n=182 (79%) and n=168 203 
(73%) of patients with follow-up data in the treatment and placebo arm of the trial, 204 
respectively. Average change in scores was similar for both the treatment and placebo 205 
groups across all the PROMs (Table 1). There were no statistically significant differences 206 
between the trial groups on PROMs relating to general health. Furthermore, there 207 
remained no statistically significant differences between the two groups on the 208 
glaucoma-specific PROMs. In addition, the distribution in the baseline to exit scores were 209 
strikingly similar between the treatment and placebo groups (Figure 1). 210 
 PROM data were not available at the exit visit for a proportion of patients in the 211 
UKGTS. Further analysis of those with missing data indicates that these patients had a 212 
similar profile to those with complete data (Table 2). Specifically, as determined through 213 
two-sample t-tests, there were no statistically significant differences between these two 214 
groups on baseline better eye mean deviation (MD) (p = 0.12), worse eye MD (p = 0.90), 215 
Patient reported outcome measures in glaucoma clinical trials 
11 
 
better eye visual acuity (p = 0.44), worse eye visual acuity (p = 0.56), and age (p = 0.27). 216 
As a group, patients without exit PROMs reported slightly worse average general and 217 
vision-related quality of life at baseline compared to those with exit PROMs. However, the 218 
magnitude of these differences was small; it might reflect some patients without exit 219 
PROMs being more likely to be people who were unwell at the start of the trial. For 220 
example, 32 patients had less than 21-months follow-up in the trial because of ill health 221 
and seven patients died during follow-up (12). 222 
 We assessed differences between stable patients (N=272) and patients with 223 
glaucomatous progression (N=78) as determined by the primary visual field outcome. 224 
Median (interquartile range) duration between baseline and progression confirmation 225 
visit was 465 (278, 553) days, in comparison to the 2-year (730 days) scheduled follow-226 
up for patients remaining stable.  No statistically significant differences were found 227 
between average responses from stable and progressed patients on PROMs relating to 228 
general health (EQ-5D, EQ-5D VAS and SF-36). Average differences between stable and 229 
progressed patients were statistically significant when assessing responses on glaucoma-230 
specific PROMs (GQL-15 and GAL-9) (Table 3 and Figure 2). As a group, patients who had 231 
progressed on visual fields therefore reported a reduction in glaucoma-specific vision-232 
related quality of life that was different to those who had remained stable on visual fields. 233 
Mean (95% CI) scores for the progression patients on the GAL-9 and GQL-15 was 6.5 (2.8–234 
9.2) % and 3.9 (3.2–9.8) % respectively. 235 
 236 
 237 
 238 
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 239 
Table 1. Means (standard deviation) of percentage (%) change scores for the two trial 240 
groups (treatment and placebo) on PROMs between baseline and trial exit in the UKGTS. 241 
Mean (standard deviation) change in worse-eye mean deviation between baseline and 242 
trial exit in the UKGTS. More negative MD indicates improved scores from baseline. 243 
Table 1. Means (standard deviation) of percentage (%) change scores for the two trial 
groups (treatment and placebo) on PROMs between baseline and trial exit in the 
UKGTS. Mean [95% confidence interval] difference between the two samples. Mean 
(standard deviation) change in worse-eye mean deviation between baseline and trial 
exit in the UKGTS. More negative MD change indicates improved scores from baseline. 
PROM 
Group 
 
 
 
Treatment 
N = 182 
Placebo 
N = 168 
 
Mean Difference 
[CI] 
 
 
p-value 
  
EQ-5D 1.7 (15.4)% 1.7 (10.6)% 0.0% [-2.8 to 2.8%] 0.98 
EQ-5D VAS 2.1 (12.5)% 1.9 (12.0)% 0.2% [-2.8 to 2.4%]  0.88 
SF-36 4.8 (19.8)% 5.0 (22.5)% 0.2% [-4.2 to 4.6%] 0.94 
GQL-15 2.7 (7.7)% 3.2 (11.7)% 0.5% [-1.5 to 2.6%] 0.66 
GAL-9 3.0 (8.5)% 3.2 (12.8)% 0.2% [-2.1 to 2.5%] 0.87 
     
MD -0.23 (1.9) dB 0.14 (2.0) dB  0.07 
Change from baseline to exit is shown as a percentage (%). Percentages show the 
average amount of change on each PROM for treatment and placebo group. Positive 
percentages indicate worsening from baseline.  
PROM = Patient reported outcome measure. CI = Confidence interval. EQ-5D = 
European quality of life in 5 dimensions. VAS = Visual analogue scale. SF-36 = Short 
from 36. GQL-15 = Glaucoma quality of life. GAL = Glaucoma activity limitation. MD = 
Mean deviation change in worse-eye. dB = Decibels. 
 244 
 245 
 246 
 247 
Patient reported outcome measures in glaucoma clinical trials 
13 
 
Figure 1. Boxplots on the left show change in scores between baseline and exit PROMs 248 
for patients in the placebo group (blue) and the treatment group (green) in the UKGTS. 249 
Positive scores (higher than 0) indicate worsening from baseline. Boxplots on the right 250 
show change in progressing/worse eye MD score between baseline and exit VFs for 251 
placebo and treatment groups. (MD is a summary measure used to represent overall 252 
reduction in visual field sensitivity relative to healthy aged-matched observers. Lower 253 
MD values (more negative) are indicative of greater loss of vision). Boxplots give median, 254 
interquartile range, 5th and 95th percentiles (whiskers). Due to large variability in   255 
responses, 95th percentile is capped at 40% change for SF-36 analysis (SF-36 placebo 95th 256 
percentile = 54.6%; SF-36 treatment 95th percentile = 42.2%). 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
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Table 2. Comparison of baseline characteristics between patients in the UKGTS with 269 
PROM data (N=350) and those without PROM data at exit (N=166). 270 
Table 2. Comparison of baseline characteristics between patients in the UKGTS with PROM data 
(N=350) and those without PROM data at exit (N=166). 
 
  
UKGTS patients 
with PROMs 
N = 350 
 
UKGTS patients 
without PROMs 
N = 166 
  
p-value 
MD (dB)     
Better eye     
 Mean  -0.5 (1.2) -0.8 (1.8)  0.12 
 Median  -0.5 [-1.3, 0.4] -0.6 [-1.4, 0.3]   
Worse eye     
 Mean  -4.2 (3.3) -4.3 (3.6)  0.90 
 Median  -3.3 [-5.6, -2.0] -3.4 [-5.7, -1.7]   
Best-corrected VA     
Better eye     
 Mean 1.0 (0.21) 1.0 (0.24)  0.44 
 Median 1.0 [1.0, 1.2] 1.0 [1.0, 1.2]   
Worse eye     
 Mean 0.9 (0.24) 0.9 (0.25)  0.56 
 Median 1.0 [0.67, 1.0] 1.0 [0.67, 1.0]   
Age (years)     
 Mean 65.8 (9.9) 67.4 (11.9)  0.27 
Sex     
 Male 188 (53.7%) 85 (51.2%)   
 Female 162 (46.3%) 81 (48.8%) 
 
  
Baseline PROM   Mean  
difference [CI] 
 
 
Mean     
EQ-5D 5 (7.2) % 5 (6.5) % 0 [0 to 3%] 0.53 
EQ-5D VAS 81 (15.1) % 75 (18.7) % 6 [2 to 13%] 0.03 
SF-36 77 (17.2) % 70 (19.9) % 7 [3 to 14%] 0.002 
GQL-15 7 (8.9) % 11 (12.7) % 4 [1 to 10%] 0.003 
GAL-9 7 (9.9) % 11 (14.7) % 4 [1 to 10%] 0.01 
Data are n (%) or mean (standard deviation) or median [interquartile range]. PROM = Patient reported 
outcome measure. MD = Mean deviation. dB = Decibels. VA = Visual acuity (decimal). CI = Confidence 
interval. 
 271 
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Table 3. Means (standard deviation) of percentage (%) change scores for stable and 272 
progressed patients on PROMs between baseline and trial exit in the UKGTS. Mean 273 
(standard deviation) change in worse-eye mean deviation between baseline and trial exit 274 
in the UKGTS. More negative MD indicates improved scores from baseline. 275 
Table 3. Means (standard deviation) of percentage (%) change scores for stable and 
progressed patients on PROMs between baseline and trial exit in the UKGTS. Mean 
[95% confidence interval] difference between the two samples. Mean (standard 
deviation) change in worse-eye mean deviation between baseline and trial exit in the 
UKGTS. More negative MD indicates improved scores from baseline. 
 
PROM 
Outcome 
 
 
Stable 
N = 272 
Progressed 
N = 78 
Mean Difference 
 [CI] 
 
 
p-value 
  
EQ-5D 1.5 (13.5)% 2.4 (12.5)% 0.9% [-2.5 to 4.3] 0.62 
EQ-5D VAS 1.5 (11.8)% 3.6 (13.5)% 2.1% [-1.0 to 5.2] 0.23 
SF-36 4.6 (20.3)% 6.0 (23.6)% 1.4% [-3.9 to 6.7] 0.65 
GQL-15 2.1 (7.9)% 6.0 (14.3)% 3.9% [1.5 to 6.3] 0.02* 
GAL-9 2.1 (9.1)% 6.5 (14.8)% 4.4% [1.7 to 7.1] 0.02* 
     
MD -0.22 (1.9) dB 0.55 (2.1) dB  0.003* 
Change from baseline to exit is shown as a percentage (%). Percentages show the 
average amount of change on each PROM for stable and progressed trial outcomes. 
Positive percentages indicate worsening from baseline. 
PROM = Patient reported outcome measure. CI = Confidence interval. EQ-5D = 
European quality of life in 5 dimensions. VAS = Visual analogue scale. SF-36 = Short 
from 36. GQL-15 = Glaucoma quality of life. GAL = Glaucoma activity limitation. MD = 
Mean deviation of worse-eye. dB = Decibels. 
* = significant at 0.05 level 
 276 
Figure 2. Boxplots on the left show change in scores between baseline and exit PROMs 277 
for patients remaining stable (purple) and patients with visual field progression (red) in 278 
the UKGTS. Positive scores (higher than 0) indicate worsening from baseline. Boxplots on 279 
the right show change in progressing/worse eye MD score between baseline and exit VFs 280 
for stable and progression groups. Boxplots give median, interquartile range, 5th and 95th 281 
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percentiles (whiskers). Due to large variability in responses, 95th percentile is capped at 282 
40% change for SF-36 analysis (SF-36 stable 95th percentile = 42.4%; SF-36 progression 283 
95th percentile = 53.8%). 284 
  285 
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Discussion 286 
Results from this study show average changes in scores on general health-related PROMs 287 
(EQ-5D, EQ-5D VAS and SF-36) to be similar for patients receiving either Latanoprost or 288 
placebo eye drops in the UKGTS. Moreover, we did not find any evidence for differences 289 
between the two arms of the trial when analysing changes in PROMs specifically relating 290 
to vision and glaucoma (GQL-15 and GAL-9). Therefore, PROMs used in the UKGTS 291 
measured once at baseline and at 2-year follow-up (or final review, for those exiting early 292 
as a consequence of visual field progression) are not as sensitive as serial visual fields, 293 
taken over the same time course, in determining treatment differences in disease 294 
progression in a trial for glaucoma treatment.  295 
There were other interesting findings from our study. Statistically significant 296 
differences were observed in average responses between stable and progressed patients 297 
on glaucoma-specific PROMs, but this was not the case for general health-related PROMs. 298 
This suggests general health-related PROMs are insensitive to treatment-induced 299 
changes in glaucoma progression, certainly in the population of patients represented in 300 
the UKGTS within the 24-month observation period. Another finding, not directly related 301 
to the aim of our study, concerns differences between GAL-9 and GQL-15. When 302 
comparing stable and progressing patients, GAL-9 yielded a marginally larger average 303 
effect (4.4%) when compared to the GQL-15 (3.9%). As such, we provide supporting 304 
evidence that the GAL-9 may be a satisfactory alternative to the GQL-15 when assessing 305 
glaucoma-specific vision-related quality of life. The GAL-9 has the added benefit of having 306 
fewer items and is therefore less burdensome for the patient to complete. 307 
Our results have implications for trial design for glaucoma treatments. The UKGTS 308 
highlighted that a relatively short observation period could be implemented when 309 
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adopting a sensitive change-from-baseline event criterion to identify visual field 310 
progression. This was made possible by frequent visual field testing and sensitive 311 
statistical methods where measurements that were repeatedly worse than baseline were 312 
flagged. Our results suggest that PROMs may not be sensitive enough to be used as 313 
outcome measures in glaucoma treatment trials, especially over a relatively short follow-314 
up.  Yet, it is important to note in the UKGTS, patients only completed PROMs at baseline 315 
and exit visits. The difference in mean deviation (a global measure, in the same sense as 316 
a questionnaire score) of the visual fields taken at baseline and final review was also not 317 
sufficiently sensitive to identify differences between the treatment and placebo groups. 318 
Therefore, the explanation of the inability of the PROM scores to identify treatment 319 
differences is that either the PROM scores are insufficiently responsive to the small 320 
changes in disease observed over the short trial duration or that the scores are 321 
insufficiently precise, or both. Indeed, PROMs administered more frequently during the 322 
trial may have reduced the within person variability in responses and increase the 323 
likelihood of capturing significant changes. We are aware of at least two ongoing 324 
glaucoma trials that are doing this, albeit in different PROMS to the ones used in UKGTS. 325 
(26-27) Still, the relatively small effects and large variability in our PROM data indicate that 326 
even repeat measures may not provide adequate trial power. It is encouraging that our 327 
chosen primary end point for the UKGTS, namely visual field progression, was sensitive 328 
enough to detect changes that are likely imperceptible to most patients in the early stage 329 
of the disease. Longitudinal studies have revealed an association between visual field 330 
progression and changes in vision-related quality of life in glaucoma patients (42-45). Yet, 331 
these studies have tended to use global or regional measures of visual field derived from 332 
binocular measures. We are unaware of any longitudinal studies reporting changes in 333 
quality of life measures that are associated with progression events detected at a visual 334 
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field test location level using GPA software. Ultimately, it makes sense that trial endpoints 335 
are aligned to relevant and meaningful outcomes for the patient, and we have highlighted 336 
that disease-specific instruments, like GAL-9 and GQL-15, can track visual field loss 337 
amongst glaucoma patients. Moreover, it remains important that all stakeholders are 338 
considered when deciding on outcome measures in clinical trials, and that includes the 339 
patients themselves. (46)  340 
Other observations on our results are noteworthy. Average changes in PROMs, 341 
where they existed, were small and the variability in response between participants was 342 
large. For example, the average 6% decline on the GQL-15 in the N=78 patients who were 343 
progressing on visual fields is equivalent of a change from ‘no difficulty’ to ‘a little bit of 344 
difficulty’ on just four of the 15 items on the GQL-15. This small average change in vison-345 
related quality of life suggests that patients experiencing the visual field endpoint do not 346 
perceive large changes in visual function, in this cohort with glaucoma mostly at its 347 
earliest stage. This is an interesting finding because it has been suggested that placebo-348 
controlled clinical trials for glaucoma treatment can be harmful for those randomised to 349 
the placebo arm. (47) However, our findings certainly indicate that vision-related and 350 
health-related quality of life was similar between patients in the placebo group to those 351 
randomised to treatment over the course of the trial. In the case of the UKGTS, all patients 352 
were monitored closely over a short trial duration and the criterion for visual field 353 
deterioration was proven to be very sensitive. On average, patients progressing, based on 354 
visual fields, experience a small or unnoticeable reduction in vision-related quality of life. 355 
They certainly do not, on average, experience a change in general health as measured by 356 
the general-health PROMs considered in our study and this is particularly noteworthy. 357 
These findings support an argument for close monitoring being an alternative to medical 358 
treatment in the early stages of the disease, an observation made from the results of 359 
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previous clinical trials. (5, 8) As no statistically significant differences in PROM scores were 360 
observed between the treatment and placebo group in UKGTS, our findings might have 361 
implications for how health-related and vision-related quality of life are assessed in 362 
clinical trials. More objective or ‘real-world’ assessments of visual disability are 363 
emerging, and these have potential for use as trial outcomes that are meaningful to the 364 
patient. One such measure, the Assessment of Function Related to Vision (AFREV), 365 
requires users to perform visual tasks such as findings objects, using everyday 366 
technologies, and reading under various illuminations. (48) If used as an outcome measure, 367 
tools such as the AFREV may yield more discernible differences between treatment 368 
groups in glaucoma clinical trials, but this remains speculation until tested. An added 369 
advantage of such objective measures is that, unlike PROMs, they are less reliant on the 370 
functional literacy of the patient. Offering definitive guidance on the use of PROMs or 371 
visual fields, or a combination of the two, as outcome measures for glaucoma trials is 372 
beyond the remit of this study. These issues are complicated because, for example, 373 
PROMs are derived from the individual, who has two eyes, and the visual field outcome 374 
is derived from just one eye (the first showing progression), and in the UKGTS just 11% 375 
(n = 10) of progressing patients had visual field progression in both eyes. PROM 376 
performance in glaucoma is likely driven by the least affected eye but this is dependent 377 
on the stage of glaucoma (49, 50); in the UKGTS, almost 50% of participants had glaucoma 378 
in only one eye. Furthermore, the visual field progression outcome occurred in one eye 379 
only in almost 90% of participants with identifiable progression (94 of 461 subjects) and 380 
in 73% of these, the progression was in the worse eye. Thus, the person-level PROM 381 
outcome would be expected to be less sensitive to glaucoma deterioration than eye-based 382 
measures of visual function. For example, standard automated perimetry will detect 383 
changes in sensitivity that may be unnoticed by the patient, whereas PROMs will likely be 384 
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more responsive to central visual field loss. This does not mean that PROMs do not have 385 
a role in treatment trials; they may have a more important role in identifying adverse (or 386 
even beneficial) effects of interventions on the person that they have in identifying 387 
disease modifying effects. 388 
The study was not without limitations. In some cases, not all patients completed 389 
PROMs at baseline or exit from the trial and so no comparable data were available for 390 
analysis. Yet, patients with and without PROM data had similar demographic and visual 391 
function profiles. One key limitation comes from patients possibly being aware of the 392 
status of their glaucoma progression (stable or worsening) at the time of completing exit 393 
PROMs. This is certainly true for patients withdrawn early from the trial because visual 394 
field progression had occurred. If, for example, a patient was told they were exiting the 395 
trial because their clinically measured vision was getting worse, then that would likely 396 
influence self-report of quality of life. If this were the case, one might expect knowledge 397 
of glaucoma progression status to affect general health-related, as well as vision-related, 398 
quality of life, but there were no differences in the EQ-5D or SF36 between those who 399 
progressed and those who did not. As previously discussed, the design of the UKGTS 400 
meant that patients completed PROMs at only two time points. This is obviously different 401 
to the frequent collection of visual field data (primary outcome).  Our results are also 402 
limited to apply to only a UK population of newly diagnosed patients, most of whom were 403 
at the earliest stage of the disease. We cannot say how PROMs may change over a period 404 
of 24-months in people with more advanced disease. Patient’s vision-related quality of 405 
life may decrease more quickly when visual field loss is already quite advanced. (51) 406 
In conclusion, patients randomised to treatment or placebo in the UKGTS returned 407 
similar responses to PROMs at baseline and final visits of the trial. It is accepted that no 408 
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single PROM covers all aspects of patients’ vision-related quality of life, (52) and our 409 
findings at least emphasise the importance of appropriate PROM selection when 410 
designing and implementing clinical trials. Even if PROMs cannot capture the disease 411 
modification effect of an intervention, that certainly does not mean that they are not 412 
useful if they can capture other consequences of an intervention including, for example, 413 
side effects or inconvenience of treatment regimens. In the UKGTS differences in PROM 414 
responses only emerged when comparing stable and progressed patients on instruments 415 
that were specific to glaucoma. As such, we suggest PROMs alone, administered at the 416 
start and end of a 24-month trial assessing disease progression, may not be sensitive 417 
enough to be used as the primary endpoints in glaucoma clinical trials assessing disease 418 
progression.  419 
  420 
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